We previously reported two hamster models for viscerotropic yellow fever virus (YFV) infection: one using a YFV strain (Jiménez), isolated from a fatal human case in Panama in 1974, and the other using the prototype YFV strain (Asibi). Asibi hamster passage 7 (P7) was associated with accumulation of seven amino acid substitutions, including five in the envelope protein. In this study we report the genome sequences of the hamster Jiménez P0 and P10 viruses in which we identified only two amino acid substitutions during passage, one each in the nonstructural proteins NS3 and NS5, indicating a role for the nonstructural proteins in increased YFV viscerotropism in the Jiménez hamster model. Thus, there are multiple molecular mechanisms involved in viscerotropism of YFV in the hamster model. Neither Asibi P7 nor Jiménez P10 viruses were viscerotropic in mice or guinea pigs. Thus, the hamster viscerotropic phenotype did not translate to other laboratory rodent species.
Get full access to this article
View all access options for this article.
References
1.
AckermannM, PadmanabhanR. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem, 2001; 276:39926–39937.
2.
AugusteAJ, LemeyP, PybusOG, Suchard, et al. Yellow fever virus maintenance in Trinidad and its dispersal throughout the Americas. J Virol, 2010; 84:9967–9977.
3.
BeckA, GuzmanH, LiL, EllisB, et al.Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa. PLoS Negl Trop Dis, 2013; 7:e1910.
4.
ChambersTJ, NestorowiczA, AmbergSM, RiceCM. Mutagenesis of the yellow fever virus NS2B protein: Effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol, 1993; 67:6797–6807.
5.
ChenY, MaguireT, HilemanRE, FrommJR, et al.Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med, 1997; 3:866–871.
6.
Couto-LimaD, MadecY, BersotMI, CamposSS, et al.Potential risk of re-emergence of urban transmission of Yellow Fever virus in Brazil facilitated by competent Aedes populations. Sci Rep, 2017; 7:4848.
7.
CuiT, SugrueRJ, XuQ, LeeAKW, et al. Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein. Virology, 1998; 246:409–417.
8.
Di PaolaN, FreireCCM, ZanottoPMA. Does adaptation to vertebrate codon usage relate to flavivirus emergence potential?. PLoS One, 2018; 13:e0191652.
9.
EgloffMP, BenarrochD, SeliskoB, RometteJL, et al.An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: Crystal structure and functional characterization. EMBO J, 2002; 21:2757–2768.
10.
GomezMM., AbreuFVS, SantosA, MelloIS, et al.Genomic and structural features of the yellow fever virus from the 2016–2017 Brazilian outbreak. J Gen Virol, 2018; 99:536–548.
11.
GuyattKJ, WestawayEG, KhromykhAA. Expression and purification of enzymatically active recombinant RNA-dependent RNA polymerase (NS5) of the flavivirus Kunjin. J Virol Methods, 2001; 92:37–44.
12.
HamrickPN, AldighieriS, MachadoG, LeonelDG, et al.Geographic patterns and environmental factors associated with human yellow fever presence in the Americas. PLoS Negl Trop Dis, 2017; 11:e0005897.
13.
JulanderJG.Animal models of yellow fever and their application in clinical research. Curr Opin Virol, 2016; 18:64–69.
14.
JulanderJG, BantiaS, TaubenheimBR, MinningDM, et al.BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother, 2014; 58:6607–6614.
15.
JulanderJG, ShaferK, SmeeDF, MorreyJD, et al.Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother, 2009; 53:202–209.
16.
KlittingR, RothL, ReyFA, De LamballerieX. Molecular determinants of Yellow Fever Virus pathogenicity in Syrian Golden Hamsters: One mutation away from virulence. Emerg Microbes Infect, 2018; 7:51.
17.
KooninEV.Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol, 1993; 74(Pt 4):733–740.
18.
LilayA, AsameneN, BekeleA, MengeshaM, et al.Reemergence of yellow fever in Ethiopia after 50 years, 2013: Epidemiological and entomological investigations. BMC Infect Dis, 2017; 17:343.
McarthurMA, SudermanMT, MutebiJP, XiaoSY, et al.Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol, 2003; 77:1462–1468.
21.
McarthurMA, XiaoSY, BarrettAD. Phenotypic and molecular characterization of a non-lethal, hamster-viscerotropic strain of yellow fever virus. Virus Res, 2005; 110:65–71.
MurthyK, ClumS, PadmanabhanR. Dengue virus NS3 serine protease: Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J Biol Chem, 1999; 274:5573–5580.
24.
MurthyK, JudgeK, DelucasL, PadmanabhanR. Crystal structure of dengue virus NS3 protease in conplex with a Bowman-Birk inhibitor: Implications for flavivirus polyprotein processing and drug design. J Mol Biol, 2000; 301:759–767.
25.
PugachevKV, NomokonovaNU, DobrikovaEY, WolfYL. Site-directed mutagenesis of the tick-borne encephalitis virus NS3 gene reveals the putative serine protease domain of the NS3 protein. FEBS Lett, 1993; 328:115–118.
26.
ReedLJ, MuenchH. A simple method of estimating fifty percent endpoints. Am J Hyg, 1938; 27:493–497.
27.
RiceCM, LenchesEM, EddySR, ShinSJ, et al.Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution. Science, 1985; 229:726–733.
28.
SbranaE, XiaoSY, GuzmanH, YeM, et al.Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am J Trop Med Hyg, 2004; 71:306–312.
29.
SbranaE, XiaoSY, PopovVL, NewmanPC. et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am J Trop Med Hyg, 2006; 74:1084–1089.
30.
ShearerFM, LongbottomJ, BrowneAJ, PigottDM, et al.Existing and potential infection risk zones of yellow fever worldwide: A modelling analysis. Lancet Glob Health, 2018; 6:e270–e278.
31.
StrodeGK.Yellow Fever. New York: McGraw-Hill Book Company, Inc., 1951.
32.
TanBH, FuJ, SugrueRJ, YapEH, et al.Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology, 1996; 216:317–325.
33.
TeshRB, GuzmanH, Da RosaAP, VasconcelosPF, et al.Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis, 2001; 183:1431–1436.
34.
ValleRPC, FalgoutB. Mutagenesis of the NS3 protease of dengue virus type 2. J Virol, 1998; 72:624–632.
35.
WangE, RymanKD, JenningsAD, WoodDJ, et al.Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol, 1995; 76(Pt 11):2749–2755.
36.
WenglerG.The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology, 1991; 184:707–715.
37.
XiaoSY, ZhangH, GuzmanH, TeshRB. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis, 2001; 183:1437–1444.
38.
ZhangL, MohanPM, PadmanabhanR. Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. J Virol, 1992; 66:7549–7554.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
